PCSK9 inhibition in type 2 diabetes: So far so good, but not there yet

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 5, 2016, Pages 377-379

  Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LIPID; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS FUNCTION; PLASMA CLEARANCE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 2; HUMANS; LIPIDS; PROPROTEIN CONVERTASE 9;

EID: 84957900066     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)00014-0     Document Type: Note

References (10)

1. Santos RD, Watts GF Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet 2015, 385:307-310.
2. Weintraub WS, Gidding SS PCSK9 inhibitors: a technology worth paying for?. PharmacoEconomics 2015, published online Dec 21. 10.1007/s40273-015-0355-y.
3. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1500-1509. for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.
4. Rabar S, Harker M, O'Flynn N, Wierzbicki AS Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014, 349:g4356.
5. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 2016, published online Feb 8. http://dx.doi.org/10.1016/S2213-8587(16)00003-6.
6. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
7. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584:701-706.
8. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
9. Bonnefond A, Yengo L, Le May C, et al. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia 2015, 58:2051-2055.
10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.